| CPBA | Competitive Protein Binding Assay |
|---|---|
| AOO | anodal opening odor; atrial asynchronous (competitive, fixed-rate) [pacemaker] |
| CBPA | competitive protein-binding assay |
| CISH | competitive in situ hybridization |
| CMO | cardiac minute output; Chief Medical Officer; comfort measures only; competitive medical organizatio... |
| ATP | Antitachycardia pacing |
|---|---|
| AP | Atrial pacing |
| TAP | Transesophageal atrial pacing |
| PCL | pacing cycle length |
| VP | ventricular pacing |
| cardiac pacing, artificial | Regulation of the rate of contraction of the heart muscles by an artificial pacemaker. (12 Dec 1998) |
|---|---|
| pacing catheter | A cardiac catheter with one or more electrodes at its tip which can be used to artificially pace the heart. (05 Mar 2000) |
| underdrive pacing | Electrical stimulation of the heart at a rate lower than that of an existing tachycardia; designed to capture the heart between beats, i.e., to interrupt a reentry pathway in order to terminate the tachycardia. (05 Mar 2000) |
| competitive antagonist | An antimetabolite. (05 Mar 2000) |
| competitive behaviour | The direct struggle between individuals for environmental necessities or for a common goal. (12 Dec 1998) |
| competitive bidding | Pricing statements presented by more than one party for the purpose of securing a contract. (12 Dec 1998) |
| competitive binding assay | General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards. See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay. Synonym: displacement analysis, saturation analysis. (05 Mar 2000) |
| competitive inhibition | <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding. at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same. (05 Jan 1998) |
| competitive medical plans | Alternative health care delivery mechanisms, such as preferred provider organizations or other health insurance services or prepaid plans (other than health maintenance organizations), that meet medicare qualifications for a risk-sharing contract. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|